Context and Objective: S-phase kinase protein 2 (SKP2) is an F-box protein with proteasomal properties and has been found to be overexpressed in a variety of cancers. However, its role in papillary thyroid cancer (PTC) has not been fully elucidated.
T hyroid cancer is the most common malignancy of endocrine system and its incidence is increasing worldwide (1) . In Saudi Arabia, thyroid cancer is the second most common cancer affecting Saudi females after breast cancer (2) . Among the several histological subtypes of thyroid cancer, papillary thyroid cancer (PTC) is the most common subtype, accounting for 80% to 90% of thyroid cancer (3) . Although most PTC is effectively managed by surgical resection followed by radioactive iodine therapy, a subset of PTC is aggressive and refractory to current therapeutic approaches, necessitating the need to identify new therapeutic strategies against this type of cancer (4) (5) (6) (7) .
Several previous studies have explored and concentrated on the oncogenic role of S-phase kinase protein 2 (SKP2) overexpression in a variety of cancers, including PTC (8, 9) , and many studies have focused on regulatory genes and pathways involved in SKP2 overexpression, including cMYC (10) , phosphatidylinositol 3-kinase/ AKT (11) , PPARg (12) , and mTOR (13) . The inhibition of the proteasome has emerged as a novel approach to anticancer therapy (14) (15) (16) (17) (18) and may provide a therapeutic option for aggressive PTC (19, 20) . Bortezomib (Velcade) is a proteasome inhibitor used in the clinic for treatment of patients with relapsed or refractory multiple myeloma and several other malignancies (21) (22) (23) . Because SKP2 is considered an important target for bortezomib, we sought to test the prevalence of SKP2 expression on a large cohort of PTC cases in the Middle Eastern ethnic group, which has one of the highest incidences of PTC in the world. It was shown that treatment of tumor cells with bortezomib caused changes in cell adherence, inhibition of the cell cycle, increased apoptosis, and inhibition of NF-kB activation (24) (25) (26) . In the clinic, bortezomib as a single agent showed many side effects, including immunosuppression (27) , peripheral neuropathy (28) , and muscle toxicity (29) . Therefore, bortezomib is currently being tested against various cancers in combination with several other apoptosisinducing agents (30, 31) to reduce its side effects.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily, which selectively activates the caspase-8/ 10-mediated extrinsic apoptotic pathway in a variety of cancer cells (32, 33) and exhibits robust antitumor effects in diverse murine models of cancer (34, 35) . Despite promising preclinical results, TRAIL receptor agonists have failed to demonstrate significant efficacy, either alone or in combination with chemotherapy, in multiple clinical trials in advanced malignancies (36) (37) (38) (39) (40) (41) . These disappointing results in clinical trials have been attributed to a number of factors, including de novo and/or acquired resistance to TRAIL receptor agonists, inadequate receptor oligomerization on ligand binding, limiting procaspase-8/ 10 activation, and lack of biomarkers to predict treatment response (35, 42) . Combination therapies involving several conventional and novel chemotherapeutic drugs have been reported to increase TRAIL-mediated apoptosis in these resistant cells (43) (44) (45) (46) (47) (48) (49) (50) .
It has been previously reported that treatment with proteasome inhibitors overcomes TRAIL resistance in various human solid cancers, including prostate cancer (51), colon cancer (52), glioma (53), non-small cell lung cancer (54, 55) , and hepatocellular carcinoma (56, 57) . However, the molecular mechanism underlying the effects of the combined treatment is largely unknown in PTC. In the present study, we analyzed the efficacy of combined treatment with bortezomib and TRAIL on inducing apoptosis in two human PTC cell lines and evaluated the molecular mechanisms underlying the effects of this combination.
We present evidence that treatment with suboptimal dose of bortezomib and TRAIL synergistically induced apoptosis via generation of ROS in PTC cells. Furthermore, we assessed the prevalence and clinical prognosis of SKP2 and its molecular association with antiapoptotic proteins in a cohort of .1000 Saudi PTCs using the tissue microarray (TMA) technique.
Materials and Methods

Patient selection and TMA construction
One thousand forty patients with PTC diagnosed between 1988 and 2011 were selected from King Faisal Specialist Hospital and Research Centre and Prince Sultan Military Medical City. Clinical and histopathological data were available for all of these patients (Supplemental Table 1 ). All samples were analyzed in a TMA format. TMA construction was performed from formalin-fixed, paraffin-embedded PTC specimens as described earlier (58) . Briefly, tissue cylinders with a diameter of 0.6 mm were punched from representative tumor regions of each donor tissue block and brought into recipient paraffin block using a modified semiautomatic robotic precision instrument (Beecher Instruments, Woodland, WI). Two cores of papillary carcinoma of the thyroid were arrayed from each case. Both of the cores were stained for the same protein, and scoring was done in duplicate to minimize the number of missing spots. Waiver of consent was obtained for all archived paraffin tissue blocks from the Institutional Review Board of the King Faisal Specialist Hospital and Research Centre under project RAC no. 2140-010.
Immunohistochemistry
TMA slides were processed and stained manually as described previously (59) . Primary antibodies used, as well as their dilutions and incidences, are listed in Supplemental Table 2 . SKP2 scoring was done as described previously with a cutoff of 20% proportion tumor cell staining considered as high SKP2 expression (9) . Other immunohistochemistry (IHC) markers such as X-linked inhibitor of apoptosis protein (XIAP), Bcl-x L , and death receptor 5 (DR5) were scored as described previously (60) (61) (62) .
Statistical analysis
Contingency table analysis and x 2 tests were used to study the relationship between clinicopathological variables and SKP2. Survival curves were generated using the Kaplan-Meier method, with significance evaluated using the Mantel-Cox logrank test. The limit of significance for all analyses was defined as a P value of 0.05; two-sided tests were used in all calculations.
The JMP10.0 (SAS Institute, Cary, NC) software package was used for data analyses.
Cell culture
The PTC cell line BCPAP was obtained from the DSMZ, and TPC-1 was provided by Dr. Bryan McIver (Department of Endocrinology, Mayo Clinic, Rochester, MN). Both cell lines were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum, 100 U/mL penicillin/streptomycin, and 100 U/mL glutamine as described previously (63) . Both cell lines were authenticated in-house using short tandem repeats PCR, and the results (Supplemental Table 3 ) were in concordance with published data (64) . All experiments were performed using 5% fetal bovine serum in RPMI 1640 media. 
Reagents and antibodies
Cell lysis and immunoblotting
Cells were treated with indicated doses of different inhibitors as described in the figure legends and lysed as previously described (65) . Immunoblotting was performed with different antibodies and visualized by an enhanced chemiluminescence (Amersham Biosciences, Arlington Heights, IL) system.
3-(4,5-Dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide assays Cells (10 4 ) were incubated in triplicate in a 96-well plate in the presence or absence of indicated test doses of bortezomib and TRAIL either alone or combination in a final volume of 0.20 mL for 48 hours. Cell growth inhibition was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) cell viability assays, as described earlier (66) . Replicates of six wells for each dosage, including vehicle control, were analyzed for each experiment.
Cell cycle analysis
Cells were treated with bortezomib and TRAIL either alone or combination for 48 hours and then were washed once with phosphate-buffered saline (PBS) and resuspended in 500 mL of hypotonic staining buffer [sodium citrate (250 mg), Triton X-100 (0.75 mL), propidium iodide (25 mg), ribonuclease A (5 mg), and water (250 mL)] followed by analysis by flow cytometry as described earlier (67) .
Annexin V staining
Cells were treated with bortezomib and TRAIL either alone or combination for 48 hours and then were harvested. The percentage apoptosis was measured by flow cytometry after staining with fluorescein-conjugated annexin V and propidium iodide as described earlier (67) .
Immunofluorescence analysis
PTC cells grown on coverslips in six-well plates were fixed with ice-cold 100% methanol followed by permeabilization with 0.2% Triton X-100, blocked with 5% horse serum in PBS solution, and incubated with antibodies to SKP2 (1:100), SOD1 (1:200), or DR5 (1:200) in buffer A (1% BSA, 0.1% Triton X-100, 10% horse serum in PBS solution) for 1 hour at 37°C. Cells were then incubated with Alexa Fluor 488 goat antirabbit/mouse antibody and mounted using 4 0 ,6-diamidino-2-phenylindole. The cells were visualized using Olympus BX63 fluorescence microscope.
Intracellular ROS determination H 2 O 2 and O 2
$2 generations were examined using the fluorescent dye DCFDA and DHE, respectively, as described previously (68) . The cells were cultured in six-well plates (2 3 10 5 cells per well), treated with bortezomib and TRAIL either alone or combination for 12 hours, and incubated with DCFDA or DHE (10 mM) for 40 minutes at 37°C. Trypsinized cells were washed twice with cold PBS and analyzed by fluorescence-activated cell sorting (FACSCalibur; BD Biosciences, San Jose, CA). The fluorescence intensity of DCFDA was measured at an excitation wavelength of 492 nm and an emission wavelength of 517 nm. The fluorescence intensity of DHE was measured at an excitation wavelength of 535 nm and an emission wavelength of 610 nm.
Gene silencing using small interfering RNA SKP2 small interfering RNA (siRNA; catalog nos. S100287819 and S102659692 pooled) and scrambled control siRNA (catalog no. 102781) were purchased from Qiagen (Valencia, CA). Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for 6 hours, following which the lipid and siRNA complex was removed and fresh growth medium was added. After 48 hours of transfection, cells were used for various experiments.
Animals and xenograft study
Six-week-old nude mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained in a pathogen-free animal facility for at least 1 week before use. All animal studies were done in accordance with institutional guidelines. For the xenograft study, mice were inoculated subcutaneously into the right abdominal quadrant with 10 million TPC-1 cells in 200 mL of PBS. After 1 week, mice were randomly assigned into four groups: the first group received 0.9% saline and three groups received 25 mg/kg TRAIL, 250 mg/kg bortezomib, and a combination of 25 mg/kg TRAIL and 250 mg/kg bortezomib intraperitoneally, respectively. Mice were given these drugs twice weekly. The body weight and tumor volume of each mouse were monitored weekly. The tumor volume was measured as previously described (69) . After 4 weeks of treatment, mice were killed and individual tumors were weighed and then snap frozen in liquid nitrogen for storage.
Results
SKP2 overexpression in PTC clinical cases and association with clinicopathological parameters
Of the 1040 PTC cases in our TMA, there were 33 missing spots. Hence, an SKP2 IHC analysis was performed on 1007 samples. SKP2 overexpression was detected in 45.5% (458 of 1007) of PTC clinical cases and was found to be clinically associated with adverse prognostic factors such as extrathyroidal extension (P = 0.0451), distant metastasis (P = 0.0435), and tall cell variant (P = 0.0271) ( Table 1 ). SKP2 overexpression was also found to be directly associated with overexpression of antiapoptotic protein XIAP (P , 0.0001) and Bcl-x L (P = 0.0005) and inversely associated with DR5 (P , 0.0001) (Supplemental Fig. 1 ; Table 1 ) SKP2 overexpression, however, was not associated with disease-free survival (Table 1) .
In our PTC cohort, BRAF, NRAS, HRAS, and KRAS mutations were analyzed in 807 cases. BRAF mutation was noted in 58.5% (472 of 807) of the cases, with an inverse association noted between BRAF mutation and SKP2 overexpression. NRAS mutation was detected in 5.6% (45 of 807) of the cases. Alternatively, HRAS mutation was only seen in 2.7% (22 of 807) of the cases. No association was seen between SKP2 overexpression and NRAS and HRAS mutations. Similarly, none of the 807 cases harbored KRAS mutations (Table 1) .
Bortezomib synergizes TRAIL-induced apoptosis in PTC cells
The proteasome inhibitor bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers (70) (71) (72) (73) (74) . Therefore, we sought to determine whether treatment with bortezomib could potentiate TRAIL-induced inhibition of cell viability and apoptosis in PTC cells. BCPAP and TPC-1 cells were incubated with and without indicated doses of bortezomib or TRAIL for 48 hours; cell viability was determined by an MTT assay. Bortezomib treatment caused inhibition of cell viability in a dose-dependent manner in BCPAP and TPC-1 cell lines (Fig. 1A) , whereas TRAIL alone had a mild effect on cell viability (Fig. 1B) . Treatment with suboptimal doses of bortezomib with TRAIL synergistically inhibited cell viability in PTC cells (Fig. 1C) . Next, to determine whether inhibition of cell viability was due to inhibition of cell cycle or apoptosis, we performed cell cycle analysis on PTC cell lines following treatment with bortezomib (5 nM) and TRAIL (2.5 ng/mL) either alone or in combination for 48 hours. There was a drastic increase in the sub-G 1 (Apo) fraction of cells from 0.77% in the untreated control sample to 43.85% after cotreatment with bortezomib (5 nM) and TRAIL (2.5 ng/mL) for 48 hours in the BCPAP cell line. Similar results were obtained in the TPC-1 cell line where the sub-G 1 population increased from 0.67% in the untreated control sample to 53.61% after cotreatment with bortezomib (5 nM) and TRAIL (2.5 ng/mL) for 48 hours, suggesting that these cells were actually dying of apoptosis (Fig. 1D) . Meanwhile, the cell cycle analysis showed that treatment with bortezomib and TRAIL alone increased the G 2 M phase population after 48 hours in PTC cells (Fig. 1D) . Furthermore, we performed experiments to examine whether cell death induced by bortezomib and TRAIL occurred via apoptosis. BCPAP and TPC-1 cells were treated with bortezomib and TRAIL either alone or combination for 48 hours and cells were stained with annexin V/propidium iodide dual staining and analyzed by flow cytometry. In BCPAP cells, bortezomib or TRAIL alone induced 28.8% 6 6.4% or 14.8% 6 1.5% apoptosis, respectively, whereas cotreatment with bortezomib and TRAIL exposure significantly increased the apoptotic population to 66.05% 6 2.1% (P , 0.05). A similar synergistic effect was also observed in TPC-1 cells (Fig. 1E and 1F) . To confirm the role of caspases in bortezomib-and TRAIL-induced apoptosis, PTC cells were pretreated with a universal inhibitor of apoptosis, zVAD-fmk (80 mM), for 3 hours followed by cotreatment with bortezomib (5 nM) and TRAIL (2.5 ng/mL) for 48 hours. As shown in Supplemental Fig. 2A , there was appreciable inhibition of apoptosis in zVAD-fmk-pretreated cells as compared with bortezomib and TRAIL-cotreated cells alone. These data clearly indicated that cotreatment of bortezomib and TRAIL inhibited cell viability via induction of apoptosis in PTC cells.
Bortezomib and TRAIL synergistically downregulates SKP2 that activates caspase-8 and causes truncation of Bid Because we found a high incidence of SKP2 overexpression in our clinical PTC cases, we sought to examine the expression of SKP2 following treatment with a suboptimal dose of bortezomib and TRAIL either alone or in combination in PTC cells. Treatment of bortezomib and TRAIL synergistically downregulated SKP2 expression in PTC cells (Fig. 2A) . Similar results were observed by immunofluorescence; PTC cells treated with bortezomib (5 nM) and TRAIL (2.5 ng/mL) either alone or in combination showed a marked decrease in the SKP2 level (Fig. 2B) . Because caspase-8 plays a pivotal role in the extrinsic apoptotic signaling pathway via death receptors (75), we investigated whether cotreatment of bortezomib and TRAIL causes activation of caspase-8 and Bid truncation in PTC cells. BCPAP and TPC-1 cells were treated with bortezomib (5 nM) and TRAIL (2.5 ng/mL) either alone or combination for 48 hours, and western blot analysis was performed using antibodies against caspase-8 and Bid. As shown in Fig. 2C , bortezomib and TRAIL synergistically induced activation and cleavage of caspase-8 and Bid in both cell lines tested. Upregulation of caspase-8 expression by pretreatment with interferon-g significantly (P , 0.05) increased apoptosis after cotreatment with bortezomib and TRAIL in PTC cells (Supplemental Fig. 2B ). Additionally, silencing of caspase-8 significantly (P , 0.05) suppressed the apoptosis induced by cotreatment with bortezomib and TRAIL in PTC cells (Supplemental Fig. 2C (Fig. 2D) . We then determined the effect of truncation of Bid on Bax activation. We cotreated with bortezomib and TRAIL for different time periods in BCPAP and TPC-1 cell lines. We found evidence that Bax protein underwent conformational changes at 16 hours in BCPAP and TPC-1 cell lines (Supplemental Fig. 3A) . We next determined whether conformational changes in Bax protein caused change in mitochondrial membrane potential, the early event of activation of the mitochondrial apoptotic pathway in PTC cells. BCPAP and TPC-1 cells were treated with bortezomib (5 nM) and TRAIL (2.5 ng/mL) either alone or in combination for 48 hours. Following treatment, cells were stained with JC1 dye for detection of loss of mitochondrial membrane potential by flow cytometry. As shown in Supplemental Fig. 3B , cotreatment with bortezomib and TRAIL caused loss of mitochondrial membrane potential as measured by JC1-stained green florescence depicting apoptotic cells in both cell lines tested, leading to release of cytochrome c from mitochondria into cytosol (Supplemental Fig. 3C ). The release of cytochrome c from mitochondria has been shown to activate caspase-9 that results in the cleavage of downstream effector caspase-3 (77) . As shown in Fig. 2C , cotreatment of bortezomib and TRAIL induced activation and cleavage of caspase-9, caspase-3, and PARP in both cell lines tested. Finally, bortezomib and TRAIL synergistically downregulated the inhibitor of apoptosis proteins, cIAP1, and XIAP, all of which play an important role in inhibition of apoptosis (Fig. 2D) . These results suggest that bortezomib and TRAIL synergistically induced the cleavage of caspase-8 and Bid, leading to activation of the mitochondrial apoptotic pathway.
Bortezomib and TRAIL synergistically generate ROS in PTC cells
In addition of functioning as a proteasome inhibitor, bortezomib has also been shown to generate ROS in various cancers (78, 79) . TRAIL-induced ROS generation has also been reported previously (80, 81) . However, generation of ROS in PTC cells following bortezomib or TRAIL treatment has not been elucidated. Therefore, we investigated the release of ROS in PTC cell lines after treatment with bortezomib and TRAIL either alone or in combination. ROS production was quantified by flow cytometry using the fluorescent probes DHE and DCFDA.
Treatment of bortezomib and TRAIL either alone or combination stimulated O 2 $2 and H 2 O 2 generation in PTC cells, as indicated by an increase of DHE ( Fig. 3A and 3B) and DCFDA ( Fig. 3D and 3E ) fluorescence intensity, respectively, when levels were compared with those generated from untreated control cells. The DHE signal was significantly (P , 0.05) increased after cotreatment with bortezomib and TRAIL and inhibited by MnTMPyP, a cell-permeable SOD mimetic (O 2 $2 scavenger) (Fig. 3C) . Similarly, the DCFDA signal was significantly (P , 0.05) increased after cotreatment with bortezomib and TRAIL and inhibited by catalase (H 2 O 2 scavenger) (Fig. 3F) . Interestingly, silencing of SKP2 significantly increased ROS generation in PTC cells (Fig. 3G-3J ). Next, we analyzed the effect of SKP2 silencing on colony formation, apoptosis, and antioxidant status in PTC cells. As shown in Supplemental Fig. 4A and 4B, silencing of SKP2 significantly reduced the colony formation in both PTC cells. However, knockdown of SKP2 did not show any significant effect on apoptosis (Supplemental Fig. 4C ) and cell cycle regulation (data not shown). There was a slight downregulation observed in the expression of antioxidant enzymes SOD1, SOD2, and Figure 3 . Bortezomib alone or combination with TRAIL induces ROS in PTC cells. Generation of O 2 .2 and H 2 O 2 were determined by staining the cells with DHE and DCFDA, respectively. PTC cells were exposed to bortezomib and TRAIL either alone or in combination for 12 hours and then were labeled with (A and B) DHE (10 mM) or (D and E) DCFDA (10 mM). Images were obtained by fluorescence microscopy, and fluorescent intensity was determined by flow cytometry. PTC cells were pretreated with MnTMPyP (5 mM; O 2 .2 scavenger) or catalase (1000 U/mL; H 2 O 2 scavenger) for 2 hours followed by cotreatment with bortezomib and TRAIL for 12 hours and then were labeled with (C) DHE (10 mM) or (F) DCFDA (10 mM) as described in Materials and Methods. (G-J) Silencing of SKP2 increases ROS generation. PTC cells were transfected with scrambled siRNA (100 nM) and SKP2 siRNA (50 and 100 nM) with Lipofectamine. After 48 hours of transfection, cells were labeled with DCFDA (10 mM). Images were obtained by fluorescence microscopy, and fluorescence intensity was determined by flow cytometry. Data presented in bar graphs are the mean 6 standard deviation of three independent experiments. *P , 0.05, compared with control (without treatment); # P , 0.05, compared with bortezomib/TRAIL treatment. doi: 10.1210/jc.2017-02178 https://academic.oup.com/jcemcatalase after transfection with SKP2 siRNA (Supplemental Fig. 4D ). We then determined the effect of bortezomib on inducing apoptosis after SKP2 knockdown in PTC cells. We found that bortezomib has no significant effect on induction of apoptosis after SKP2 knockdown in PTC cells, whereas significant induction of apoptosis was observed after bortezomib treatment in scramble control (Supplemental Fig. 4E ).
Bortezomib and TRAIL synergistically induce ROS and activate the ERK-CHOP-DR5 pathway in PTC cells Cotreatment with bortezomib and TRAIL synergistically induced ROS and dramatically downregulated antioxidant enzymes such as SOD1, SOD2, and catalase (Fig. 4A) . Similar results were observed by immunofluorescence analysis where cotreatment with bortezomib and TRAIL synergistically suppressed the expression of SOD1 (Fig. 4B) . ROS release has been shown to cause upregulation of DR5, an essential receptor for TRAILinduced apoptosis (66, 82) . We sought to determine whether cotreatment with bortezomib and TRAIL could upregulate the expression of DR5 via generation of ROS in PTC cells. As expected, cotreatment with bortezomib and TRAIL synergistically upregulated expression of DR5 in BCPAP and TPC-1 cells (Fig. 4A) . These results were further confirmed by immunofluorescence analysis (Fig. 4C) . It has been reported that mitogen-activated protein kinase and CHOP activation plays a role in ROSinduced DR5 induction (83, 84) . As shown in Fig. 4A , cotreatment with bortezomib and TRAIL markedly increased the activation of ERK1/2 and CHOP expressions in both of the PTC cell lines (Fig. 4A) . To confirm the role of ROS on activation of the ERK-CHOP-DR5 pathway after cotreatment with bortezomib and TRAIL in PTC cells, we pretreated PTC cells with catalase or N-acetylcysteine (ROS scavengers) for 3 hours, followed by cotreatment with bortezomib and TRAIL for 48 hours (Fig. 4E and 4F ). Our data clearly indicated that ERK-CHOP-DR5 upregulation is ROS-dependent, as pretreatment of ROS scavengers could effectively block bortezomib/TRAIL-induced ERK-CHOP-DR5 upregulation in PTC cells (Fig. 4E and 4F ).
Bortezomib augmented the anticancer effect of TRAIL in vivo
The combination of bortezomib and TRAIL induced a synergistic apoptotic response in vitro. Therefore, we sought to determine whether this combination of treatment would result in an anticancer effect in vivo. To investigate this, nude mice were inoculated subcutaneously with 10 million TPC-1 cells into the right abdominal quadrant. After 1 week of inoculation, mice were randomly assigned into four groups: the first group received 0.9% normal saline as vehicle control, whereas the other three groups received bortezomib (250 mg/kg), TRAIL (25 mg/kg), and a combination of both injected intraperitoneally twice weekly. After 4 weeks of treatment, mice were killed and tumors were collected. The volume of the tumors was not affected by the treatment with bortezomib or TRAIL alone, but the combination of both drugs reduced the tumor volume within 3 weeks of treatment and reached significance at the end of the fourth week (Fig. 5A) . The weight of the tumor also reduced appreciably following cotreatment with bortezomib and TRAIL as compared with independent treatments (Fig. 5B) . We also visualized images of the tumor after necropsy and found that there was significant shrinkage in the size of the tumor following treatment with the combination of bortezomib and TRAIL as compared with treatment alone (Fig. 5C ). Finally, we examined the expression of SKP2, catalase, caspase-3, and PARP by immunoblotting and found that there was decrease in the expression of SKP2 and catalase as well as cleavage of caspase-3 and PARP in tumor samples that were treated with the combination of bortezomib and TRAIL (Fig. 5D ). These data suggest that the combination of bortezomib and TRAIL is effective in inhibiting tumor growth in TPC-1 xenografts.
Discussion
Our IHC data showed that 45.5% of PTC cases (458 of 1007) had overexpression of SKP2 in our cohort of clinical cases. These data are in concordance with another study showing SKP2 overexpression at a frequency of 42% in PTC cases (9) . In our clinical samples, high expression of SKP2 was correlated with aggressive clinicopathological markers such as distant metastasis (P = 0.0435), tall cell variant (P = 0.0271), and the presence of extrathyroidal extension (P = 0.0451). Interestingly, SKP2 overexpression in our cohort was found to be inversely correlated with BRAF mutation (P = 0.0307). This could indicate that BRAF-dependent activation of the MAPK pathway in PTC might act partially through the control of SKP2 expression. It has been previously speculated that increased cytoplasmic SKP2 expression is possibly due to BRAF mutation in melanomas (85) .
Additionally, our data also showed that SKP2 overexpression was directly associated with overexpression of antiapoptotic proteins XIAP and Bcl-x L and inversely associated with DR5 in our PTC clinical samples. Even though SKP2 overexpression was not associated with disease-free survival, these data clearly indicate that SKP2 overexpression is associated with an aggressive phenotype that needs to be identified and targeted. Bortezomib represents a novel class of proteasome inhibitors that is currently being used either alone or in combination with other chemotherapeutic agents for treatment in a variety of cancers (86) . Therefore, we sought to explore the effect of bortezomib in PTC tumors that are overexpressing SKP2, either alone or in combination with other therapeutic agents.
In the present study, we investigated the synergistic effect of bortezomib and TRAIL on PTC cell growth inhibition in vitro and in vivo. Previously, bortezomib was investigated as a single agent in anaplastic thyroid cancer and shown to suppress growth (87, 88) ; however, the effect of bortezomib on PTC or whether bortezomib can be used in combination protocols to lower the threshold of apoptosis induction has not been evaluated in PTC. Developing new synergistic combination therapies for aggressive and refractory PTC is important, as aggressive cells can develop multiple mechanisms to evade apoptosis. We showed that bortezomib present a powerful tool to prime the PTC cells for TRAIL-induced apoptosis in vitro and in vivo. The combination of bortezomib and TRAIL inhibited cell proliferation and induced cell cycle arrest and apoptosis of PTC cells. We further showed that bortezomib/TRAIL could significantly induce activation of caspase-8, caspase-9, and caspase-3, whereas addition of the caspase inhibitor z-VAD could effectively reduce the apoptosis, suggesting a caspase-dependent apoptosis of PTC cells.
Recently it has been suggested that oxidative stress plays a role as a common mediator of apoptosis (89) (90) (91) . Previous studies have reported ROS generation upon treatment with bortezomib alone or in combination with other therapies in different cancer cells (79, (92) (93) (94) . Accumulation of intracellular ROS leads to disruption of mitochondrial membrane potential, release of cytochrome c into the cytosol, and subsequent activation of a caspase cascade and ultimately to programmed cell death and apoptosis (95, 96) . Interestingly, in this study we also observed a significant increase in ROS generation in PTC cells after treatment with bortezomib/TRAIL. The ROS generation likely played a crucial role in the induction of apoptosis of PTC cells because treatment with catalase, an ROS scavenger, could markedly reduce the apoptosis. We have previously shown that ROS release leads to upregulation of DR5 (66, 97) . Bortezomib/ TRAIL cotreatment activated the ERK-CHOP-DR5 signaling cascade via generation of ROS, thereby inducing apoptosis in PTC cells. Furthermore, we investigated the effect of bortezomib/TRAIL in PTC xenografts in nude mice. Our results showed that the combination of bortezomib/TRAIL could suppress the growth of PTC tumors, in a more-than-additive manner, when compared with either drug alone. Taken together, these in vivo data complemented our in vitro data on highlighting the synergistic antitumor effects of bortezomib/TRAIL in PTC over those of either bortezomib or TRAIL alone.
In summary, the combination of bortezomib/TRAIL synergistically induced killing of PTC cells. The major mechanism of cell death is ROS-driven caspasedependent apoptosis. Furthermore, bortezomib/TRAIL potently induced apoptosis and suppressed the growth of PTC xenografts in nude mice. Taken together, our study established the basis for the design of a new, rationalebased bortezomib combination regimen in patients with aggressive PTC.
